Indivior Company Profile
✉ Email this page to a colleague
What is the competitive landscape for INDIVIOR, and when can generic versions of INDIVIOR drugs launch?
INDIVIOR has seven approved drugs.
There are twenty-seven US patents protecting INDIVIOR drugs.
There are two hundred and eighty-two patent family members on INDIVIOR drugs in thirty-six countries and one supplementary protection certificate in one country.
Summary for Indivior
| International Patents: | 282 |
| US Patents: | 27 |
| Tradenames: | 6 |
| Ingredients: | 5 |
| NDAs: | 7 |
| Patent Litigation for Indivior: | See patent lawsuits for Indivior |
| PTAB Cases with Indivior as patent owner: | See PTAB cases with Indivior as patent owner |
Drugs and US Patents for Indivior
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indivior | SUBOXONE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 022410-002 | Aug 30, 2010 | AB | RX | Yes | No | 11,135,216 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Indivior | PERSERIS KIT | risperidone | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 210655-002 | Jul 27, 2018 | RX | Yes | Yes | 9,186,413 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Indivior | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-001 | Nov 30, 2017 | RX | Yes | No | 9,782,402 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Indivior
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Indivior | SUBOXONE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 022410-003 | Aug 10, 2012 | 9,855,221 | ⤷ Try a Trial |
| Indivior | SUBOXONE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 022410-003 | Aug 10, 2012 | 8,603,514 | ⤷ Try a Trial |
| Indivior | SUBOXONE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 022410-001 | Aug 30, 2010 | 8,603,514 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for INDIVIOR drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Sublingual Film | 4 mg/1 mg | ➤ Subscribe | 2013-05-14 |
| ➤ Subscribe | Sublingual Film | 2 mg/0.5 mg and 8 mg/2 mg | ➤ Subscribe | 2012-10-15 |
| ➤ Subscribe | Sulingual Film | 12 mg/3 mg | ➤ Subscribe | 2014-03-26 |
International Patents for Indivior Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2015129183 | ⤷ Try a Trial |
| Australia | 2015341490 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2014144241 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Indivior Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0196132 | 94C0008 | Belgium | ⤷ Try a Trial | PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
